Dry Eye

The month will serve to educate the public on a variety of women’s vision issues.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

Long-term screen users and contact lens wearers in group face challenges.

According to the companies, NOV03 consistently met primary endpoints for the signs and symptoms of dry eye disease linked with Meibomian gland dysfunction. A PDUFA data is set for June 28.

Avenova Eye Health Support oral supplement aims to comfort dry eyes and support overall eye health.

The company’s Purely Soothing eye drop is used as an anti-inflammatory used to assist with symptoms of ocular irritation and/or swelling, including dry eye.

Alice Epitropoulos, MD, gives some insight into meibomian gland dysfunction (MGD), one of the most prevalent forms of dry eye.

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Alice Epitropoulos, MD, gives tips on how to optimize treatment for patients with meibomian gland dysfunction (MGD).

The company is anticipating the first patient-first visit in Q1 2023 and is looking to release top-line data from the Phase 2 trial in Q4 2023.

In a presentation at the EnVision Summit 2023 in Puerto Rico, Sumayya Ahmad, MD, pointed out that for patients with lower Schirmer’s scores and corneal staining, PRK may be a good choice. If the dry eye can be treated preoperatively and the eye has no staining, surgeons can consider LASIK.

Managing dry eye requires addressing underlying disease process with therapy, treatments

According to the company, reproxalap is a small-molecule modulator of reactive aldehyde species that will be used for the treatment of the signs and symptoms of dry eye disease.

Physicians explain how winter exacerbates symptoms of disease.

The results from an exchange trial demonstrated a second administration of travoprost intraocular implant and removal of the original implant was safe and well-tolerated, while the company also provided updates for several of its corneal health pipeline programs for the treatment of keratoconus and dry eye disease.

NOV03 is being investigated to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction, and a PDUFA action date has been set for June 28.

Researchers at Washington University School of Medicine in St. Louis have found that proteins made by stem cells that regenerate the cornea may be new targets for treating and preventing such injuries.

According to the company, clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System.

The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to the company's catalog of ophthalmological diagnostic tools available to clinicians throughout North America.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.

According to investigators, the risk for the development of dry eye disease is greater in postmenopausal women compared with those who have not reached menopause as a result of hormonal dysregulation of the ocular secretory glands.

According to the company, the OK-101 phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of dry eye disease.

The company is rolling out the Biovance 3L ocular tri-layer human amniotic membrane.

Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.